US OptionsDetailed Quotes
UTHR240816C370000
- 2.12
- -0.86-28.86%
15min DelayClose Jul 22 15:59 ET
2.12High2.12Low
2.12Open2.98Pre Close1 Volume3 Open Interest370.00Strike Price212.00Turnover38.89%IV11.87%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry2.12Extrinsic Value100Contract SizeAmericanOptions Type0.1699Delta0.0074Gamma112.76Leverage Ratio-0.1778Theta0.0371Rho19.16Eff Leverage0.2213Vega
United Therapeutics Stock Discussion
Sign in to post a comment
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
82
7
$United Therapeutics(UTHR.US$
lol that is a shit ton of inside selling all at the end of June
lol that is a shit ton of inside selling all at the end of June
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
Are you a high net profit margin lover? So you will like these 1⃣2⃣ stocks with a net profit margin above 4⃣0⃣%
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
13
The low P/E despite solid growth numbers seems to stem from investor sentiment, possibly from certain unobserved threats affecting the stock. Some shareholders might be skeptical of the earnings forecasts, indicating potential earnings instability.
United Therapeutics' strong financials could suggest long-term stock increase. Its net income growth might be due to good management and a low payout ratio, even though the earnings growth may slow down in future.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Unum Group(UNM.US$ - up 5.1%
2. $Generac(GNRC.US$ - up 5.0%
3. $Builders FirstSource(BLDR.US$ - up 4.9%
4. $Livent(LTHM.US$ - up 4.4%
5. $Pearson(PSO.US$ - up 4.1%
6. $Verisk Analytics(VRSK.US$ - up 3.6%
7. $Assurant(AIZ.US$ - up 2.7%
8. $Vodafone(VOD.US$ - up...
Gap Ups
1. $Unum Group(UNM.US$ - up 5.1%
2. $Generac(GNRC.US$ - up 5.0%
3. $Builders FirstSource(BLDR.US$ - up 4.9%
4. $Livent(LTHM.US$ - up 4.4%
5. $Pearson(PSO.US$ - up 4.1%
6. $Verisk Analytics(VRSK.US$ - up 3.6%
7. $Assurant(AIZ.US$ - up 2.7%
8. $Vodafone(VOD.US$ - up...
+16
15
2
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
Moderna and Merck to develop a cancer vaccine for high-risk melanoma patients
Last week, we had some exciting news on cancer vaccine development announced by Moderna and Merck.
Moderna's vaccine, based on its messenger RNA technology, is being studied in combination with Merck's Keytruda to treat...
Top Medical News of the Week
Moderna and Merck to develop a cancer vaccine for high-risk melanoma patients
Last week, we had some exciting news on cancer vaccine development announced by Moderna and Merck.
Moderna's vaccine, based on its messenger RNA technology, is being studied in combination with Merck's Keytruda to treat...
13
No comment yet
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...